Vertex EVP logs tax-withholding share disposition

Vertex Pharmaceuticals executive Edward Morrow Atkinson III reported a tax-related share disposition.

(Neutral)

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Vertex Pharmaceuticals executive Edward Morrow Atkinson III reported a tax-related share disposition. On February 13, 2026, he disposed of 1,903 shares of Vertex common stock at $487.76 per share as a tax-withholding disposition and now directly holds 20,143 shares of common stock.

Insider Trade Summary

Exercise Price or Tax Liability: 1,903 shares

Exercise Price or Tax Liability 1 txn

Insider Atkinson Edward Morrow III

Role EVP, Chief Technical Ops. Off.

Type	Security	Shares	Price	Value
Exercise Price or Tax Liability	Common Stock	1,903	$487.76	$928K

Holdings After Transaction: Common Stock — 20,143 shares (Direct)

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Vertex (VRTX) report for Edward Morrow Atkinson III?

Vertex reported that EVP Edward Morrow Atkinson III disposed of 1,903 shares of common stock. The transaction was a tax-withholding disposition tied to equity compensation, rather than an open-market sale, and was executed at $487.76 per share on February 13, 2026.

How many Vertex (VRTX) shares did the EVP dispose of, and at what price?

The EVP disposed of 1,903 shares of Vertex common stock at a price of $487.76 per share. This was classified as a tax-withholding disposition, meaning shares were withheld to cover tax obligations arising from equity compensation.

What is Edward Morrow Atkinson III’s role at Vertex (VRTX) in this Form 4?

Edward Morrow Atkinson III is identified as an officer of Vertex, serving as EVP, Chief Technical Ops. Officer. The Form 4 reflects his personal holdings and a tax-withholding transaction involving Vertex common stock on February 13, 2026.

How many Vertex (VRTX) shares does the EVP hold after the reported transaction?

Following the tax-withholding disposition of 1,903 shares, the EVP directly owns 20,143 shares of Vertex common stock. This post-transaction balance is explicitly stated, providing clarity on his remaining direct equity stake after the Form 4 event.

Was the Vertex (VRTX) insider transaction a sale on the open market?

No, the transaction is coded as “F,” a tax-withholding disposition rather than an open-market sale. Shares were delivered to satisfy tax liabilities associated with equity compensation, so it does not represent a discretionary buy or sell decision.

What transaction code is used in the Vertex (VRTX) Form 4 and what does it mean?

The Form 4 uses transaction code “F,” described as payment of exercise price or tax liability by delivering securities. Here it indicates a tax-withholding disposition, where 1,903 shares were used to cover tax obligations instead of being sold on the market.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 02/18/2026 - 04:19 PM EST

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Atkinson Edward Morrow III

(Last)

(First)

(Middle)

C/O VERTEX PHARMACEUTICALS INCORPORATED

50 NORTHERN AVENUE

(Street)

BOSTON

02210

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
VERTEX PHARMACEUTICALS INC / MA [ VRTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	EVP, Chief Technical Ops. Off.

3. Date of Earliest Transaction (Month/Day/Year)
02/13/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	02/13/2026		F		1,903	D	$487.76	20,143	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

Remarks:

	/s/ Christiana Stevenson, Attorney-in-Fact	02/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR